Insilico Medicine Announces a Strategic AI-driven R&D Collaboration with Gray Matter on Fighting Age-related CNS Diseases and Aging
HONG KONG, Sept. 1, 2021 /PRNewswire/ -- Insilico Medicine is pleased to announce an R&D collaboration with Gray Matter, a longevity biotechnology company focused on peptide-based interventions against cognitive decline, age-related CNS diseases, and aging. This strategic partnership is intended to speed up the discovery of new therapeutic targets for peptide therapy in the field of age-related cognitive decline and involve Insilico Medicine's AI-augmented platforms and close cooperation between the Gray Matter and Insilico Medicine scientists.
The prevalence of mild cognitive impairment (MCI) rises from 6.7% (1 in every 14 people) for ages 60–64 to 25.2% (1 in every four people) for the 80–84 cohort. People diagnosed with MCI are 3-5 times more likely to develop dementia of some form. With the adult population growing older and the increase in the need for health and social services, the public health community is challenged to be proactive. This is particularly important as these issues can impact not only older adults but also their families and friends who act as caregivers.
Peptide therapy is well suited to develop treatments for chronic conditions such as MCI. There is a considerable amount of longitudinal data on peptides which indicates that the class may present a more favorable risk-benefit profile as compared to interventions based on gene therapy, cell therapy and other novel approaches. Moreover, the production of peptide-based drugs can be more cost-effective compared to other novel drug types.
"We aim to develop a new generation of safe and effective therapies to help patients live longer, healthier lives with their cognition intact. We see a remarkable synergy between our rapid iterative approach based on proprietary peptide discovery engine Reptide and AI-powered target discovery by Insilico Medicine. This collaboration is intended to help Gray Matter further to reduce costs and timeline for early drug development," said Alexey Strygin, co-founder and CEO of Gray Matter.
"Insilico is advancing its latest target identification systems utilizing machine learning, generative biology methods, and synthetic data generation pipelines, and we are pleased to be collaborating with Gray Matter on its target identification efforts. Searching for peptide targets is an important modality of the target discovery in general, and we are happy to apply our technology in this challenging area," said Alex Zhavoronkov, CEO of Insilico Medicine.
In August, Insilico Medicine nominated the second preclinical candidate for kidney fibrosis.
About Insilico Medicine
Insilico Medicine, an end-to-end artificial intelligence-driven drug discovery company, is developing artificial intelligence platforms. These platforms use deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and ageing-related diseases. Website http://insilico.com/
For further information, images, or interviews, please contact [email protected].
About Gray Matter
Gray Matter is a preclinical biotechnology company with a therapeutic pipeline in cognitive decline, age-related CNS diseases, and aging. Gray Matter is a part of the Lactocore group. The Lactocore group develops drugs in stress-related and metabolic disorders, leveraging deep scientific expertise in regulatory peptides, including those in mammalian milk, and a proprietary computational discovery platform.
Media and Investor relations: [email protected]
SOURCE Insilico Medicine